Ovation Acquires Lundbeck's Antipsychotic Buronil
This article was originally published in The Pink Sheet Daily
Executive Summary
Gaining FDA approval of melperone and two other recently acquired products – the anti-epileptics Sabril (vigabatrin) and Frisium (clobazam) – is a top priority for Ovation. The company has built a portfolio of 11 "under-performing" CNS products in less than two years.